Clinical trials · Massachusetts
Malignancy clinical trials in Massachusetts
We’re tracking 115 recruiting malignancy studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT05486520Enrolling by invitation
Low-field MRI test for breast cancer screening
This study tests a special MRI scanner that uses much weaker magnets to look at breast tissue for screening and possible follow-up. It may help find breast changes while aiming to reduce noise and discomfort compared with standard MRI.
Boston, MassachusettsAges 20–80 - NCT05417594RecruitingPhase 1/Phase 2
Targeted drug study for advanced cancers with genetic changes
This Phase 1/2 study tests AZD9574 alone or with other cancer treatments in people with advanced solid tumors. It focuses on cancers with specific DNA repair gene changes (like BRCA1/2) or other matching tumor features, and aims to see if the treatment can shrink tumors and improve outcomes.
Boston, MassachusettsAges 18–130 - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Boston, MassachusettsAges 18 years+ - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Boston, MassachusettsAges 12 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Jamaica Plain, MassachusettsAges 40–75 - NCT05006716RecruitingPhase 1/Phase 2
New treatment for blood cancers that have returned
This trial tests a new pill, tacabrutideg, for blood cancers that have returned or not improved after earlier treatments. It may work for patients who have already tried a type of targeted therapy called a BTK inhibitor.
Boston, MassachusettsAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Boston, MassachusettsAges 1–30 - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT04588922RecruitingPhase 1/Phase 2
Study drug SLS009 for high-risk leukemia in adults and teens
This early-phase study tests SLS009 (also called GFH009), a targeted medicine, to treat certain blood cancers—especially high-risk or difficult-to-treat AML. It’s designed to see how the drug works, how safe it is, and what dose may be best for you.
Boston, MassachusettsAges 12 years+ - NCT03328078RecruitingPhase 1/Phase 2
Emavusertib for recurrent brain lymphoma after prior treatment
This Phase 1/2 trial tests emavusertib (a targeted medicine) in adults with primary central nervous system lymphoma that has come back or not responded to treatment. It’s designed to find safe dosing and see how well the treatment can control the lymphoma in the brain/spinal fluid.
Boston, MassachusettsAges 18 years+ - NCT03067181RecruitingPhase 3
Active surveillance and chemotherapy for germ cell tumors
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
Boston, MassachusettsAges Any age - NCT03141021Recruiting
Registry for people diagnosed with malignant peripheral nerve sheath tumors
This study is a registry, meaning it collects information from people diagnosed with malignant peripheral nerve sheath tumors (MPNST). It may help doctors learn about the condition better and improve future care.
Boston, MassachusettsAges Any age - NCT02269592Recruiting
Study blood marker changes in early, symptom-free blood cancers
This study follows people with early, “precursor” blood conditions to learn what changes in their blood or bone marrow signal progression. It may help doctors better predict outcomes and understand why some people develop symptom-causing cancer.
Brighton, MassachusettsAges 18 years+ - NCT02074839RecruitingPhase 1
Oral AG-120 for advanced blood cancers with an IDH1 mutation
This Phase 1 study tests an oral medicine called AG-120 in adults with advanced blood cancers that have a specific IDH1 mutation. It also looks at safety and how the treatment works, with frequent blood, urine, and bone marrow samples.
Boston, MassachusettsAges 18 years+ - NCT07405164RecruitingPhase 3
Long-term extension study for people taking belzutifan
This study is for people who are already taking belzutifan in a related trial (LITESPARK-043) and want to continue treatment for advanced solid tumors or von Hippel-Lindau-related conditions. It tests the safety and effects of long-term use.
Boston, MassachusettsAges 18 years+ - NCT06283927Recruiting
Surgery vs. medical care for recurrent glioblastoma
This trial compares surgery to the best non-surgical treatment for people whose glioblastoma has come back. The goal is to see which approach helps people live longer with a better quality of life.
Boston, MassachusettsAges 18–90 - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Boston, MassachusettsAges 1 month–17 years - NCT07426484RecruitingPhase 4
Testing cosibelimab for advanced skin cancer in specific patients
This trial tests an immunotherapy drug called cosibelimab for patients with advanced cutaneous squamous cell carcinoma who have either had a kidney transplant or have a blood cancer like lymphoma or myeloma. The goal is to see if it can shrink tumors when surgery or radiation is not an option.
Boston, MassachusettsAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Boston, MassachusettsAges 18 years+ - NCT07403812Recruiting
Checking thinking skills after CAR-T therapy
This study uses a simple iPad test to check for thinking problems that can happen after CAR-T cell therapy. It aims to catch these issues early so they can be managed better.
Boston, MassachusettsAges 18 years+ - NCT07197554RecruitingPhase 1
A study of an experimental drug for advanced solid tumors
This trial tests a new drug, ST-01156, designed to attack cancer cells by breaking down a protein called RBM39. It may be an option for people with advanced solid tumors that have not responded to other treatments.
Boston, MassachusettsAges 16 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT07070232RecruitingPhase 1/Phase 2
Testing a new drug BNT326 for advanced cancers
This trial tests a new medicine called BNT326, alone or with another drug BNT327, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and might help shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT07059884Recruiting
Exercise program to help people with cancer stay active
This trial tests a distance-based exercise program designed to help people on chemotherapy maintain their physical function and prevent disability. It is for patients with certain cancers who are working full-time and can participate in moderate physical activity.
Boston, MassachusettsAges 18 years+
Malignancy trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting malignancy studies listed above.
- Dana-Farber Cancer Institute · 17 studies
- Massachusetts General Hospital · 7 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Baystate Medical Center
- Boston Veteran's Affairs Medical Center
- Brigham and Women's Hospital
- Dana Farber Cancer Institute at Merrimack Valley
- Dana Farber Cancer Institute at Milford Regional Medical Center
What taking part in a malignancy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Common questions
- Are there malignancy clinical trials in Massachusetts?
- Yes. We're currently tracking 115 recruiting malignancy studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a malignancy study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New malignancy studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.